Pharmacological Treatments for Patients with Treatment-Resistant Depression
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Over a third of patients with major depressive disorder (MDD) do not have an adequate response to first-line antidepressant treatments, i.e., they have treatment-resistant depression (TRD). These patients tend to have a more severe course of illness and are at an increased risk of suicide. Next step treatment options for patients with TRD, include switching to a different antidepressant, combining more than one antidepressant, or augmenting an antidepressant with another (non-antidepressant) medication. It is unclear which of these treatment approaches should be applied to a given patient, and in what order. Due to this ambiguity, comparing antidepressants and augmentation agents on the basis of their efficacy, tolerability, and speed of symptom relief would be beneficial for clinicians. To accomplish this, a systematic search was conducted following PRISMA guidelines. Only randomized controlled trials were included in this qualitative synthesis, resulting in 66 articles. This review identified several effective pharmaco-therapeutic strategies that are currently available for patients with TRD. Ketamine and esketamine appear to be effective for the treatment of TRD. Augmentation with certain second generation antipsychotics, such as quetiapine or aripiprazole is likewise effective, and may be preferred over switching to antidepressant monotherapy. While the combination of olanzapine and fluoxetine was one of the first pharmacotherapy approved for TRD, and its use may be limited by metabolic side-effects. Other effective strategies include augmentation with lithium, liothyronine (T3), lamotrigine, or combination of antidepressants including bupropion, tricyclics, or mirtazapine. There is insufficient research to demonstrate the efficacy of ziprasidone or levothyroxine (T4). A shared decision-making approach is recommended to guide treatment selection to address each patient’s individual needs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737 · cited 2×
“It is estimated that up to one in five adults in America meet the criteria for major depressive disorder (MDD) during their lifetime [1].”
BackgroundMurrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 1×
“, 2013 [75] Ketamine; Midazolam Lapidus et al.”
Self-citationBupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · cited 1×
“, 2006 [17] Bupropion plus Citalopram; Buspirone plus Citalopram”
BackgroundPopova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904 · cited 2×
“, 2019 [83] Esketamine; placebo Fedgchin et al.”
BackgroundDaly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718 · cited 2×
“It is not stated whether these results are significant or not [85].”
BackgroundCanuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060720 · Cited by 676
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606
Cited by
Martinotti, G., Vita, A., Fagiolini, A., Maina, G., Bertolino, A., Dell'Osso, B., Siracusano, A., Clerici, M., Bellomo, A., Sani, G., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.09.043 · Cited by 146
Rhee, T. G., Shim, S. R., Forester, B. P., Nierenberg, A. A., McIntyre, R. S., Papakostas, G. I., Krystal, J. H., Sanacora, G., & Wilkinson, S. T. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.3352 · Cited by 141
Vázquez, G. H., Bahji, A., Undurraga, J., Tondo, L., & Baldessarini, R. J. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211013579 · Cited by 95
“We also examined previously published, partially relevant, systematic reviews (Bahji et al., 2020, 2021; Nelson and Papakostas, 2009; Ruberto et al., 2020; Spielmans et al., 2013; Undurraga et al., 2019) and references identified in them.”
Dominiak, M., Antosik-Wójcińska, A. Z., Wojnar, M., & Mierzejewski, P. (2021) · Pharmaceuticals · doi:10.3390/ph14060582 · Cited by 28
Gabriel, F. C., Stein, A. T., de Melo, D. O., Henrique Fontes-Mota, G. C., dos Santos, I. B., de Oliveira, A. F., Fráguas, R., & Ribeiro, E. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-051918 · Cited by 15
Denee, T., Ming, T., Waller, J., Bailey, T., Rajkovic-Hooley, O., Middleton-Dalby, C., Le, H. H., Zhang, Q., McCrone, P., & Taylor, D. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1857580 · Cited by 12
Chen, I.-P., Huang, C.-C., Huang, H.-C., Yang, F.-P. G., Ko, K.-T., Lee, Y.-T., Sun, F.-J., & Liu, S.-I. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191912430 · Cited by 13
McKeown, L., Taylor, R. W., Day, E., Shah, R., Marwood, L., Tee, H., Kerr-Gaffney, J., Oprea, E., Geddes, J. R., McAllister-Williams, R. H., et al. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221089042 · Cited by 12
Yadav, A., Dogra, S., Boda, A. K., Kumari, P., Kumar, A., Dash, M. K., & Yadav, P. N. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00175 · Cited by 9
Metadata
- Authors
- Ruberto, V. L., Jha, M. K., & Murrough, J. W.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2020-06-04
- Volume
- 13
- Issue
- 6
- Pages
- 116
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W3033447508
- Cited by
- 147
- References
- 32
- FWCI
- 10.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.